

David León-Jiménez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9260902/publications.pdf>

Version: 2024-02-01

30
papers

131
citations

1683354

5
h-index

1281420

11
g-index

36
all docs

36
docs citations

36
times ranked

262
citing authors

#	ARTICLE	IF	CITATIONS
1	Basal insulin analogues in people with diabetes and chronic kidney disease. <i>Diabetic Medicine</i> , 2022, 39, e14679.	1.2	1
2	Diabetes tipo 2 bien controlada y microalbuminuria. <i>Revista Española De Casos Clínicos En Medicina Interna</i> , 2022, 2018, 24-26.	0.0	0
3	Treatment of Supine Hypertension in Patients With Sinus brachycardia. <i>American Journal of Hypertension</i> , 2021, 34, 662-663.	1.0	1
4	Is the blood pressure variability the great forgotten parameter?. <i>Hypertension Research</i> , 2021, 44, 877-878.	1.5	1
5	The Influence of Diet and Probiotics on the Response of Solid Tumours to Immunotherapy: Present and Future Perspectives. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8445.	1.3	2
6	PostCOVID effect on endothelial function in hypertensive patients: A new research opportunity. <i>Journal of Clinical Hypertension</i> , 2021, , .	1.0	2
7	Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?. <i>Kidney International</i> , 2020, 97, 213.	2.6	1
8	In response to the paper "High-protein diet: A barrier to the nephroprotective effects of sodium-glucose cotransporter 2 inhibitors". <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1701-1702.	2.2	1
9	Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107916.	1.1	7
10	In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways". <i>Journal of Cellular Physiology</i> , 2019, 234, 9906-9907.	2.0	0
11	Síndrome de vena cava superior y omalgia: ¿qué esconde detrás?. <i>Atencion Primaria Practica</i> , 2019, 1, 28-29.	0.0	0
12	GLP-1 and the renin-angiotensin-aldosterone system. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 337.	5.5	3
13	Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke) Trial. <i>Neurology</i> , 2019, 21, 22.	0.784314	16
14	VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 285, 17-22.	0.4	6
15	A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function. <i>Scientific Reports</i> , 2019, 9, 5055.	1.6	6
16	Bleeding risk assessment for stroke patients on antithrombotic therapy. <i>Clínica e Investigación En Arteriosclerosis (English Edition)</i> , 2019, 31, 282-288.	0.1	1
17	Tratamiento diurético del paciente con diabetes e insuficiencia cardíaca. El papel de los inhibidores de la SGLT2 y semejanzas con los inhibidores de la anhidrasa carbónica. <i>Revista Clínica Española</i> , 2019, 219, 208-217.	0.2	3
18	Could renin-angiotensin-aldosterone system activation explain the amputations associated with canagliflozin? The nitric oxide hypothesis. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 10-13.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Clinical interview and mobile phone. <i>Medicina Clínica (English Edition)</i> , 2019, 152, e7-e8.	0.1	0
20	La entrevista clínica y el teléfono móvil. <i>Medicina Clínica</i> , 2019, 152, e7-e8.	0.3	0
21	Apendagitis epiploica como causa inusual de dolor abdominal agudo: características clínicas y radiológicas de 7 pacientes. <i>Revista Clinica Espanola</i> , 2019, 219, 517-520.	0.2	1
22	Evaluación del riesgo hemorrágico de la terapia antitrombótica en pacientes con ictus. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 282-288.	0.4	2
23	Reply to "Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes" by Yoshimoto et al.. <i>Journal of Investigative Medicine</i> , 2018, 66, e4-e4.	0.7	0
24	Actualización del concepto del bloqueo dual del sistema renina-angiotensina-aldosterona. ¿Una nueva opción terapéutica?. <i>Medicina Clínica</i> , 2018, 150, 33-38.	0.3	5
25	Antidiabetic drugs and stroke risk. Current evidence. <i>European Journal of Internal Medicine</i> , 2018, 48, 1-5.	1.0	36
26	The mechanism of action of sodium-glucose cotransporter 2 inhibitors is similar to carbonic anhydrase inhibitors. <i>European Journal of Heart Failure</i> , 2018, 20, 409-409.	2.9	4
27	Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 33-38.	0.1	2
28	Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1406-F1415.	1.3	22
29	Massive cerebral hematoma with electrocardiographic abnormalities. <i>Emergencias</i> , 2018, 30, 443.	0.6	0
30	Hematoma esofágico intramural y antiagregación plaquetaria. <i>Revista Clinica Espanola</i> , 2013, 213, 417-418.	0.2	0